Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients
Frontiers HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles
Pathology Report, Pathologist Melbourne, VIC
SABCS: Enhertu neoadjuvant trial has caveats, Daiichi exec says
Cancer Biomarkers: Improving Detection and Treatment
Oncology
Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center - Modern Pathology
Treatment of HER2-Low, HR-Positive, and TNBC: A Focus on HER2-Targeted and TROP2–Targeted Therapy
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors - ScienceDirect
Table 2 from Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Ibex Launches Galen Breast HER2 to Support Breast Cancer Biomarker Scoring
